Screener
Syndax Pharmaceuticals SNDX Other operating expenses
Other operating expenses at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | 58,845 | 61,636 |
| Selling, general and administrative | 37,588 | 41,031 |
| Collaboration loss | — | 247 |
| Total operating expenses | 99,066 | 103,799 |
| Loss from operations | (34,202) | (83,757) |
| Other (expense) income, net: | ||
| Royalty interest expense | (11,846) | (8,049) |
| Other interest expense | — | (2) |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's other operating expenses?
- Syndax Pharmaceuticals (SNDX) reported other operating expenses of $99.07M in Q1 2026.
- How has Syndax Pharmaceuticals's other operating expenses changed year-over-year?
- Syndax Pharmaceuticals's other operating expenses decreased by 4.6% year-over-year, from $103.8M to $99.07M.
- What is the long-term trend for Syndax Pharmaceuticals's other operating expenses?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's other operating expenses has grown at a 40.8% compound annual growth rate (CAGR), from $113.49M to $445.68M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Syndax Pharmaceuticals's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude